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A new apolipoprotein (apo) gene, APOA5, was recently identified on chromosome 11q23, and common variants in the gene have been
associated with plasma triglyceride (TG) levels in several studies. The purpose of the present study was to examine the association of five
single nucleotide polymorphisms (SNPs) and haplotypes in the APOA5 gene with low-density lipoprotein (LDL) particle size using a
community-based sample of Japanese American families, including examining whether the associations with LDL size are independent of, or
primarily reflecting, TG levels. Genetic association analyses were performed using 154 unrelated individuals, quantitative transmission
disequilibrium tests (TDT) in 238 nuclear families, a sample of 24 hypertriglyceridemic subjects with matched, normotriglyceridemic
controls, and using haplotype analyses. There was a high degree of allelic association between several of the SNPs, with complete linkage
disequilibrium (LD) between  1131C>T and the  3A>G SNP which alters a potential Kozak sequence. All approaches demonstrated
associations between the  3A>G APOA5 variant and both decreased LDL size and increased TG levels. The frequency of the rare allele was
higher than reported for Caucasian, Hispanic, and African Americans, but similar to that in Japan and China. Therefore, the haplotype
containing the  1131C and  3G variants, and possibly specifically the  3A>G SNP in APOA5, may be a major genetic determinant of
LDL particle size and TG levels among ethnic Asians.
D 2003 Elsevier B.V. All rights reserved.Keywords: Apolipoprotein; Cardiovascular disease; Genetics; Low-density lipoprotein; Triglyceride1. Introduction
A new apolipoprotein (apo) gene, APOA5, has recently
been identified on chromosome 11q23 adjacent to the
APOA1-C3-A4 gene complex [1]. In the initial study de-
scribing this gene, an inverse relationship between APOA5
and triglyceride (TG) levels was identified in mouse trans-0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2003.10.003
* Corresponding author. Tel.: +1-206-543-0709; fax: +1-206-685-
9651.
E-mail address: maustin@u.washington.edu (M.A. Austin).genic and knockout studies, and single nucleotide poly-
morphisms (SNPs) were associated with TG levels in two
samples of healthy Caucasians [1]. This finding has been
confirmed in a group of familial combined hyperlipidemia
(FCHL) families [2], as well as additional studies of
Caucasians [3–5], African Americans, and Hispanics [3].
Adenoviral overexpression of apoA5 in mice led to reduced
TG and cholesterol [6]. Since elevated plasma TG is now
widely recognized as an important independent risk factor
for coronary heart disease (CHD) [7–10], the discovery of
this new gene has important implications for understanding
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have also been shown to predict risk of cardiovascular
disease mortality in familial hypertriglyceridemia during
20 years of follow-up, independent of baseline cholesterol
levels and other covariates [11].
Increased plasma TG levels are correlated with the pre-
dominance of small, dense low-density lipoprotein (LDL)
particles, and decreased high-density lipoprotein (HDL)
cholesterol levels [12,13], the characteristic lipid abnormality
of the metabolic syndrome [14]. A meta-analysis of three
prospective studies in middle-aged men [15–17] showed a
60% increased risk for CHD for every 10-A˚ decrease in LDL
size [18]. Adjustment for TG and HDL cholesterol reduced
this to a 30% increased risk, but the odds ratio remained
statistically significant. Thus, small LDL is an independent
risk factor, over and above simple measures of plasma lipids.
The mechanism for this is partly understood. Small dense
LDL (sdLDL) particles show increased oxidative suscepti-
bility [19–21] and affinity for the LDL receptor due to
conformational changes of apo B on these particles [22].
sdLDL are thus cleared relatively slowly by the liver, thereby
allowing enhanced binding to LDL receptor-independent
sites, particularly cell surface proteoglycans on extra-hepatic
tissue such as the arterial wall [23], which would promote
atherosclerosis and increased risk of CHD.
Numerous studies have demonstrated both genetic and
environmental factors influence LDL size [24,25]. LDL size
is also influenced by sex, age, menopausal status and
hormone use in women [12,26,27]. Several candidate gene
studies have investigated the effects of structural genes [28],
receptors [29,30], and enzymes [31,32] on LDL size, with
varying results. Thus, the genetic basis of LDL particle size
remains to be definitively established. Using a quantitative
genetic analysis approach, we have demonstrated pleiotro-
pic genetic effects on LDL particle size and TG, with a high
genetic correlation of  0.87 (P < 0.001) [33].
The purpose of the present study was to examine
associations of SNPs and haplotypes in the APOA5 gene
with LDL particle size, TG, HDL cholesterol, LDL choles-
terol, and apolipoproteins, using a community-based sample
of Japanese American families. To our knowledge, this is
the first study to examine whether associations of specific
APOA5 genotypes and haplotypes with LDL size are
independent of, or primarily reflecting, TG levels.2. Materials and methods
2.1. Study sample and family recruitment
The Japanese American Family Study is an investigation
of risk factors for CHD, diabetes, and the insulin resistance
syndrome in Japanese American families. Probands were
Nisei (second generation), who participated in the Japanese
American Community Diabetes Study [34]. Eligible pro-
bands had a spouse of Japanese descent and children.Probands were contacted by letter and those interested were
asked to give permission to contact family members.
Eligible relatives included the parents, spouses and
offspring of the proband (Sansei or third generation),
siblings, spouses of siblings, and nieces and nephews of
the proband, age 18 years and over, residing anywhere in
the United States, who were not pregnant and not too ill to
participate. Thus, the study sample consists primarily of
two-generation extended Nisei and Sansei kindreds. Each
proband and relative was contacted individually by letter
and phone, and asked to participate by providing a fasting
blood sample and medical history questionnaire. For rela-
tives living outside of the Seattle metropolitan area, blood
samples were shipped by overnight mail to the University
of Washington.
The University of Washington Institutional Review
Board approved these methods and all study participants
provided written, informed consent.
2.2. Medical history, medications, and anthropometric
measurements
A self-administered questionnaire was used to obtain
demographic, medical history and medication information.
Medications were initially coded into 82 different drug
classes (beta-blockers, diuretics, hormone replacement and
oral contraceptive use for women, diabetes medications,
etc.). For data analysis, these medications were also grouped
into categories based on their known effects on the risk
factors of interest. Specifically, separate covariates were
defined for drugs that decrease TG (omega 3 fatty acids,
fibrates, niacin, atorvastatin) and for drugs increase TG or
decrease HDL cholesterol (corticosteriods, testosterone, be-
ta-blockers, diuretics, isotretinoin, finasteride, benzodiaze-
pines). For descriptive statistics, these two categories are
combined as ‘‘TG altering medications.’’ Oral contraceptive
and hormone replacement therapy in women were additional
covariates. For local participants, height (cm) and weight
(kg) were measured by a trained study technician [35]. Body
mass index (BMI) is calculated as kg/m2. For non-local
participants (approximately 50% of subjects), self-reported
height and weight was obtained from the questionnaire.
2.3. Laboratory measurements
LDL subclasses were characterized using 2–14% poly-
acrylamide gels using standard protocols [36–38]. The
estimated diameter for the major peak from the gel scan is
denoted ‘‘LDL peak particle diameter’’ (LDL size) and was
used as a continuous variable in the analyses. Plasma TG,
HDL cholesterol, LDL cholesterol, apo AI and Apo B
measurements were performed at the Core Laboratory,
Northwest Lipid Research Laboratories in Seattle using
standardized procedures [39–41]. Apo AI values were
missing for 11 study subjects and Apo B levels were
missing for 10 subjects.
Table 1
Characteristics of Japanese American study subjects
All Japanese
American study
subjects (N = 558)
Unrelated
individuals
(N= 154)
Family-based
association
analysis
(N= 278)
Matched, unrelated
hypertriglyceridemic cases
(N= 24); normotriglyceridemic
controls (N= 24)
Age (meanF S.D.) 55.0F 16.3 67.8F 10.5 41.6F 7.9 66.6F 10.1; 68.1F10.3
Sex (%female) 55.6 55.8 52.9 54.2; 54.2
LDL size (A˚, meanF S.D.) 263.4F 9.0 261.6F 9.0 264.8F 8.9 253.3F 7.0; 265.7F 7.0
Triglyceride (mg/dl, meanF S.D.) 143.0F 107.4 154.0F 92.4 135.1F123.9 271.2F 66.2; 106.0F 31.4
HDL cholesterol (mg/dl, meanF S.D.) 53.8F 15.2 55.2F 16.2 53.3F 15.1 42.6F 8.7; 55.1F13.8
LDL cholesterol (mg/dl, meanF S.D.) 117.5F 32.4 121.6F 34.2 113.5F 31.4 118.3F 38.7; 136.1F 35.8
Apo AI (mg/dl, meanF S.D.) 150.0F 26.6 154.8F 29.2 146.6F 24.6 141.6F 20.8; 149.4F 22.9
Apo B (mg/dl, meanF S.D.) 99.7F 23.2 104.7F 23.7 95.3F 23.2 118.0F 24.4; 105.5F 22.0
BMI (kg/m2) 24.5F 3.6 24.6F 4.0 24.4F 3.8 26.4F 4.2; 25.1F 3.1
TG raising medications (%) 98 (17.6) 38 (24.7) 14 (5.0) 41.7; 25.0
TG lowering medications (%) 32 (5.7) 8 (5.2) 10 (3.6) 4.2; 12.5
Hormone replacement therapy (%)a 84 (27.1) 35 (40.7) 16 (10.9) 30.8; 23.1
Oral contraceptives (%)a 24 (7.7) 1 (1.2) 22 (15.0) 0.0; 7.7
Percent post-menopausala 52.6a 83.4a 13.6a 69.2; 84.6a
a Based on women only.
Table 2A
Frequency of APOA5 SNP genotypes in Japanese American study subjects
Variant Genotype All Japanese
American study
subjects (%)
N = 558
Unrelated
individuals (%)
N= 154
Rare allele
(underlined)
Frequency
(95%
confidence
interval)
Frequency
(95%
confidence
interval)
 1131T>C TT 220(39.4) 61(39.6)
TC
¯
260(46.6) 70(45.5)
CC 78(14.0) 23(14.9)
C
¯
0.37(0.34,0.40) 0.38(0.32,0.43)
 3A>G AA 220(39.4) 61(39.6)
AT
¯
260(46.6) 70(45.5)
TT 78(14.0) 23(14.9)
T
¯
0.37(0.34,0.40) 0.38(0.32,0.43)
S19W CC 554(99.3) 152(98.7)
CG
¯
4(0.7) 2(1.3)
GG 0(0.0) 0(0.0)
G 0.004(0.001,0.010) 0.006(0.0003,0.0253)
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Lymphocyte DNA samples for each study participant
were used to genotype SNPs in the APOA5 gene,  1131T>
C (SNP3),  3A>G (Kozak), 56C>G (S19W), IVS3 +
476G>A (SNP2), and 1259T>C (SNP1), and a newly
identified insertion/deletion polymorphism. Genotyping
was performed at the Functional Genomics Laboratory of
the Center for Ecogenetics and Environmental Health at the
University of Washington. The primers and PCR conditions
for each variant and genotyping procedures are presented in
Appendix A.
A total of 579 family members of Japanese descent in 68
kindreds were genotyped. All genotypes were checked for
Mendelian consistency using the PEDCHECK program [42]
and Mendelian inconsistencies were checked by re-sequenc-
ing samples. Twenty-one subjects in 10 families had unre-
solved discrepancies, and these individuals were excluded.
Thus, the analyses reported here are based on a total of 558
study subjects.
Haplotyping was performed for five SNP variants,
 1131T>C,  3A>G, S19W, IVS3 + 476G>A, and
1259T>C, based on family structure data. Definitive hap-
lotypes could not be assigned to an additional 13 married-in
individuals in nine families based on the family data, and
these subjects were excluded only from the analysis of
haplotypes.
Sequencing of the APOA5 gene was performed for a
subset of 48 study subjects as described in Appendix B.
¯IVS3 + 476G>A GG 274(49.1) 77(50.0)
GA
¯
228(40.9) 61(39.6)
AA 56(10.0) 16(10.4)
A
¯
0.30(0.28,0.33) 0.30(0.25,0.36)
1259T>C TT 274(49.1) 77(50.0)
TC
¯
228(40.9) 61(39.6)
CC 56(10.0) 16(10.4)
C
¯
0.30(0.28,0.33) 0.30(0.25,0.36)3. Statistical analyses
Three sets of study subjects were used to examine the
associations of the APOA5 SNPs and haplotypes with LDL
size and TG: (1) genetically unrelated individuals, (2) Niseiand Sansei generations for family-based association analy-
ses, and (3) 24 hypertriglyceridemic ‘‘cases’’ and 24
matched, normotriglyceridemic ‘‘controls.’’ Because the
TG distribution was skewed (skewness = 3.5), natural log
(ln) TG was used in all statistical analyses (skewness =
0.05). All association analyses were adjusted for age, sex,
BMI, TG altering medications, and hormone replacement
therapy and oral contraceptive use in women. Eleven study
Table 2B
Pairwise measure of LD (jDVj) among unrelated individuals [43]
IVS3 + 476
 1131T>C  3A>G S19W G>A 1259T>C
 1131T>C 1.00* 0.05 0.86* 0.86*
 3A>G 1.00* 0.05 0.86* 0.86*
S19W 0.05 0.05 0.04 0.04
IVS3 + 476G>A 0.86* 0.86* 0.04 1.00*
1259T>C 0.86* 0.86* 0.04 1.00*
*P< 0.01.
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ed from the association analyses.
3.1. Genetic association analysis in unrelated individuals
One hundred fifty four probands and married-in, unrelat-
ed, family members were used to test each variant for
Hardy–Weinberg equilibrium, to estimate allele, genotype
and haplotype frequencies, and to estimate linkage disequi-
librium (LD) between the SNPs [43,44]. Analysis of covari-
ance was used to test for the associations between APOA5
SNPs and haplotypes with LDL size and lipid levels [45].
3.2. Family-based association analysis
Quantitative transmission disequilibrium tests (TDT)
were used to simultaneously test for linkage and association
between the APOA5 SNPs and LDL size [46], using the
recently developed QTDT program that can accommodate
nuclear families of any size, with or without parentalTable 3A
Association analysis of APOA5 variants with LDL particle size, lipids, and apoli
Mean valuesF S.D.
AA AG GG
TT TC CC
LDL particle size (A˚)
 3A>G 264.0F 8.1 260.8F 9.0 257.6F 10.0
1259T>C 262.9F 8.5 261.0F 9.0 257.3F 10.4
Triglyceride (mg/dl)y
 3A>G 133.7F 90.7 157.4F 74.7 194.1F128.4
1259T>C 145.0F 92.2 152.3F 82.2 198.3F 120.8
HDL cholesterol (mg/dl)
 3A>G 57.3F 16.1 55.3F 16.5 49.4F 15.5
1259T>C 55.9F 16.2 56.0F 16.7 49.1F14.5
LDL cholesterol (mg/dl)
 3A>G 117.9F 30.0 123.1F 37.2 125.8F 36.2
1259T>C 117.7F 32.7 122.7F 35.4 134.3F 35.3
Apo AI (mg/dl)
 3A>G 156.4F 29.3 157.0F 30.7 142.6F 21.4
1259T>C 156.3F 28.9 155.7F 31.7 143.6F 18.8
Apo B (mg/dl)
 3A>G 99.2F 21.6 107.7F 24.9 110.6F 23.8
1259T>C 101.3F 21.5 106.0F 26.1 114.9F 22.7
*Based on analysis of covariance with adjustment for age, sex, BMI, TG alteri
women.
y P values based on natural log TG.genotype data [47,48]. This method employs a variance
components approach that uses information from all avail-
able offspring. Specifically, family data provide estimates
of an expected genotype for every non-founder, and devi-
ates from this are a measure of allelic transmission using an
F-test.
For this analysis, genotype data from parents in the Nisei
generation and their offspring in the Sansei generation were
used. LDL size, lipid and apolipoprotein levels in the Sansei
generation (N = 278) were used as the quantitative traits of
interest.
3.3. Matched case-control analysis
A sample of 24 unrelated family members with hyper-
triglyceridemia (TGz 194 mg/dl) were identified for se-
quence comparisons of the APOA5 gene with sex- and
generation-matched, unrelated, normotriglyceridemic con-
trols (TG< 157 mg/dl) from the same kindreds. One pair
was not matched on sex and one was not matched on
generation from the available sample. The association of
SNPs with case control status was assessed using standard
v2 tests.4. Results
4.1. Characteristics of study subjects
The characteristics of the Japanese American study
subjects are presented in Table 1. Among all study subjects,poproteins based on unrelated Japanese American individuals (N = 154)
Overall P values*
AA vs. AG AG vs. GG AA vs. GG
TT vs. TC TC vs. CC TT vs. CC
0.007 0.012 0.313 0.006
0.035 0.087 0.188 0.018
0.013 0.031 0.242 0.008
0.057 0.212 0.119 0.020
0.129 0.064 0.880 0.144
0.466 0.600 0.370 0.222
0.714 0.417 0.870 0.678
0.394 0.628 0.290 0.174
0.198 0.148 0.592 0.130
0.370 0.307 0.552 0.221
0.085 0.043 0.835 0.113
0.133 0.251 0.230 0.057
ng medications, hormone replacement therapy and oral contraceptive use in
Table 3B
Family-based association analysis of APOA5 variants with LDL size, lipids,
and apolipoproteins
Number of
informative
offspring
 3A>G Number of
informative
offspring
1259T>C
F
statistic
P
value*
F
statistic
P
value*
LDL
particle
size
175 3.50 0.063 169 0.07 >0.10
Ln
triglyceride
175 7.63 0.006 169 0.51 >0.10
HDL
cholesterol
175 0.49 >0.10 169 0.47 >0.10
LDL
cholesterol
175 0.22 >0.10 169 0.00 >0.10
Apo AI 172 0.45 >0.10 166 1.96 >0.10
Apo B 173 3.86 0.051 167 0.01 >0.10
*Adjusted for age, sex, BMI, TG altering medications, hormone
replacement therapy and oral contraceptive use in women.
Fig. 1. Visual genotype of matched cases and controls. (a) APOA5 SNP
genotypes for normotriglyceridemic controls (N = 24). (b) APOA5 SNP
genotypes for hypertriglyceridemic cases (N= 24).
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slightly more than half of the study subjects were female.
Unadjusted average LDL particle size was 263A˚. Average
TG, HDL cholesterol, and LDL cholesterol, Apo AI and
Apo B plasma levels were all within normal ranges. Ap-
proximately 23% of study subjects were taking TG altering
medications. Among the unrelated individuals, the average
age was higher, and the proportion of postmenopausal
women was higher because more Nisei participants were
included in this sample. Lipid and lipoprotein values in this
sample were similar to the overall study group.
For the family-based association analyses, only LDL size
data from the Sansei generation were used. Thus, the
average age was lower in this sample, and fewer women
were postmenopausal. Mean LDL size was similar to the
overall sample and mean TG was slightly lower. By design,
TG values were higher among 24 hypertriglyceridemic
cases compared to controls and LDL particle size values
were considerably lower (mean = 253 A˚).
4.2. Frequencies of APOA5 variants and LD
The frequency of APOA5 SNP genotypes and rare alleles
are presented in Table 2A. Genotype distributions for all
variants were in Hardy–Weinberg equilibrium. Among all
study subjects, frequencies of the ‘‘rare’’ alleles (underlined)
were 0.37, 0.37, 0.004, 0.30, and 0.30 for  1131T>C
¯
,
 3A>G
¯
, S19W
¯
, IVS3 + 476G>A
¯
and 1259T>C
¯
, respective-
ly. The rare allele of the newly identified insertion/deletion
was found in five individuals, with three-generation inher-
itance in one family. However, all heterozygotes for this
variant had TG and LDL size measurements in the normal
range (data not shown), and this polymorphism was not
evaluated further.
As shown in Table 2B, the  1131T>C and  3A>G
variants were in complete LD in these Japanese Americansubjects, as were IVS3 + 476G>A and 1259T>C. The LD
between these sets of markers was high, but not complete.
As a result of these findings, the following association
analyses focus on the  3A>G and the 1259T>C variants.
4.3. Genetic association analyses
Mean values of LDL particle size, lipids, and apolipo-
proteins by APOA5 SNP genotypes are presented in Table
3A. The strongest associations are seen for  3A>G with
LDL size and TG, and there were trends of decreasing mean
values of LDL size and increasing TG levels from wild-type
to rare homozygotes, with heterozygotes showing interme-
diate levels. There was an overall borderline association
with Apo B plasma levels (P= 0.085), but no significant
associations with other lipid traits were seen.
The results of the TDT tests are presented in Table 3B
[48]. Both LDL size and TG were associated with  3A>G,
and again a borderline association was seen for Apo B
levels. No significant associations were seen with the
1259T>C variant for any of the risk factors.
Table 4
APOA5 haplotypes among Japanese Americans
Haplotype  1131T>C  3A>G 56C>G IVS3+ 476 G>A 1259T>C Frequency for unrelated individuals
(N= 282 chromosomes)
APOA5*1 T* A* C* G* T* 0.63
APOA5*2 C T C* A C 0.28
APOA5*3 T* A* G G* T* 0.01
APOA5*4 C T C* G* T* 0.08
*Wild-type allele.
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matched, normotriglyceridemic controls is presented in Fig.
1 as a visual genotype. Differences in the patterns of
genotypes for the cases and controls can be clearly seen.
Even in this small sample, the rare alleles of  3A>G and
1259T>C were more common among cases than controls
(P= 0.06 and P= 0.05, respectively).
Based on the family structures, haplotypes were con-
structed, and are presented in Table 4 using recently
reported terminology [3]. Haplotype APOA5*4 has not been
previously reported and consists of the rare alleles for
 1331T>C and  3A>G, and the wild-type alleles for all
other sites. Table 5 shows that only 6 of the possible 10
combined haplotypes were observed in the study sample.
The associations of LDL particle size with these haplo-
types are illustrated in Table 5. In comparison with the
APOA5*1/APOA5*1 combined haplotype, the presence of
the APOA5*2 and the APOA5*4 haplotypes was associated
with decreased LDL particle size, although sample sizes are
small in some groups. Similar, but less consistent, trends
were seen for TG. For Apo B, only the APOA5*2/APOA5*2
mean value was significantly higher than the APOA5*1/
APOA5*1combined haplotype.
In general, when analyses for LDL size were repeated
with additional adjustment for TG, and when TG analyses
were repeated with additional adjustment for LDL size, the
results were no longer statistically significant. For example,
among unrelated individuals, after adjustment for TG, no
significant associations were seen with LDL size for either
 3A>G or 1259T>C (P= 0.210 and P= 0.335, respective-
ly) or for TG after adjustment for LDL size (P= 0.427 and
P= 0.535, respectively).Table 5
Frequency of APOA5 combined haplotypes and mean values of adjusteda LDL s
among unrelated Japanese Americans (N= 141)
APOA5 combined haplotypes
*1/*1 *1/*2
Number of subjects (%) 60 (42.6) 40 (28.4)
LDL particle size (meanF S.D., A˚) 264.0F 8.1 260.4F 8.8
P= 0.01y
Triglyceride (meanF S.D., mg/dl)y 134.3F 91.4 152.6F 66.2
P= 0.06
Apo B (meanF S.D., mg/dl) 99.2F 21.6 107.0F 27.3
P= 0.12
a Adjusted for age, sex, BMI, TG altering medications, hormone replacement
y P values compared to APOA5*1/*1 combined haplotype; TG P values base5. Discussion
This analysis has demonstrated that common SNP var-
iants in the APOA5 gene are associated with LDL particle
size, has confirmed the association of the variants with
plasma TG levels, and has shown a borderline association
with Apo B plasma levels. Specifically, the rare alleles of
 3A>G and  1131T>C polymorphisms were associated
with decreased LDL particle size and increased plasma TG
and Apo B levels. The complete LD observed between these
two variants, which confirms previously published findings
[3], but precludes determining the functional variant in such
an association study. The  1131T>C does not appear to lie
near any known nuclear factor binding sites, nor is it close
to the recently identified functional peroxisome proliferator-
receptor alpha element at  272 to  260 in the APOA5
promoter [49]. By contrast, the few reported Kozak se-
quence variants have been shown to be functional [50,51].
Thus, APOA5  3A>G, which disrupts the sequence around
the translation start site within the Kozak sequence, is likely
to be the functional site, although in vitro studies are
necessary to prove this. Although this haplotype could
possibly be a marker for another functional sequence change
elsewhere in the APOA1/C3/A4/A5 cluster, the sequence
analysis that was carried out in 24 individuals with normal
TG and 24 with high TG, failed to identify any other
APOA5 genotype associated with TG levels.
Unlike many genetic association studies, this homoge-
neous ethnic group of Japanese Americans avoids potential
false-positive findings due to confounding from population
stratification [52]. The similarity of results based on unre-
lated subjects, family-based association tests, and theize, triglyceride and Apo B plasma levels by APOA5 combined haplotypes
*2/*2 *1/*3 *1/*4 *2/*4
16 (11.3) 2 (1.4) 16 (11.3) 7 (5.0)
257.3F 10.4 269.0F 1.4 258.5F 9.0 258.4F 9.6
P< 0.01 P= 0.37 P= 0.04 P= 0.22
198.3F 120.8 110.0F 14.1 190.9F 86.0 184.7F 154.4
P< 0.01 P= 0.82 P= 0.04 P= 0.27
114.9F 22.7 110.0F 21.2 110.6F 18.8 97.4F 24.3
P= 0.03 P= 0.54 P= 0.11 P= 0.69
therapy and oral contraceptive use in women.
d on natural log TG.
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in the findings. However, the association of LDL particle
size with the APOA5 variants was not independent of TG,
nor was the association of TG independent of LDL size,
suggesting that the variation in the APOA5 gene contributes
to common, pleiotropic genetic influences on LDL size and
TG [33].
This analysis also showed that the ‘‘rare’’ allele of the
 1131C/ 3G haplotype is relatively common in Japa-
nese Americans. Several studies have examined the fre-
quency of the  1131T>C variant in Caucasians, African
Americans and Hispanics [1–4], and Japanese living in
Japan [53,54]. In general, the frequency of the rare C allele
was less than 10% in the Caucasian samples [1]. In
contrast, the frequency of this allele was over 30% in
the two Japanese samples and a sample of Chinese men
[55], and 38% in the present study.
With one exception, these same studies demonstrated
statistically significant associations of APOA5 genotypes
with plasma TG levels, and the associations in the two
Japanese studies were highly significant ( P < 0.001)
[53,54]. The strong association of  1131T>C with TG
levels in Japanese school children and among young men in
the EARS Study [5,54] highlights that this haplotype is
expressed at a young age and suggests that its effects may be
relatively independent of cultural effects. In the present
study, the strong relationship of the  1131C/ 3G haplo-
type with elevated TG was again confirmed.
Using recently published terminology [3], the two most
common haplotypes in this sample were APOA5*1 and
APOA5*2. Since the G allele at the S19W site was very
rare in this sample, the APOA5*3 haplotype was also rare
(frequency = 0.01). A fourth haplotype, APOA5*4, not
previously reported, consisted of the rare alleles for
 3A>G and  1131T>C and wild-type alleles at other
sites, was present on 8% of the chromosomes in this study.
Most of the combined haplotypes containing either the
APOA5*2 or the APOA5*4 haplotype were associated with
decreased LDL particle size. Additional studies, possibly
in other ethnic groups with different haplotypes, will be
needed to identify the functional variants in this region of
chromosome 11.
Furthermore, APOA5 is located only approximately 27
kb distal to the APOA4 gene in the APOA1-C3-A4 gene
complex on chromosome 11 [1]. Numerous studies have
examined the role of this gene cluster in the metabolism of
HDL cholesterol and TG [56]. Because of the close prox-
imity of this gene cluster to the APOA5, it is also possible
that the effects observed in this study are due to LD of the
APOA5 variants with polymorphisms in the APOA1-C3-A4
cluster. The recent study of FCHL detected an interaction
effect of the APOA5  1131T>C variant and the APOC3
C1100T polymorphism on TG levels [2]. However Talmud
et al. [4] investigated the relative contribution of variation
within the APOC3-A4-A5 cluster in the determination of TG
levels using 9 SNP-haplotypes. The major TG raising alleleswere defined by APOA5 W19 and APOC3  482, which is
in strong LD with APOA5  1131T>C (and thus also with
 3A>G).
We previously examined which of the established
quantitative lipid risk traits were the best predictors of
CHD risk in a large prospective study of UK middle-aged
men (NPHSII) [57]. The age-adjusted univariate risk ratios
(RR) for apo B, TG, cholesterol, apo AI, LDL cholesterol
and HDL cholesterol were similar. However, in multivar-
iate analysis, apo B and TG gave the best risk prediction
with TG and apo B in the top quartile giving a RR of 4.02
(95% confidence interval 1.57 to 6.23). Since each very-
low density lipoprotein (VLDL) and LDL particle has one
apo B molecule and VLDL is cleared faster than LDL, apo
B levels essentially reflect LDL number. Since plasma TG
levels inversely correlate with small dense sdLDL, this
suggests that these hypertriglyceridemic/hyperapo B, high-
risk men may have a preponderance of sdLDL that are
oxidation-prone and therefore atherogenic. From a genetic
viewpoint, we examined the contribution of variants of the
APOA5-A4-C3 gene cluster on TG levels [4] and CHD risk
[58] in NPHSII, using nine SNPs to define haplotypes.
The APOA5 W19 and APOC3 482T alleles defined the
major TG-raising haplotypes [4], but strikingly the ranking
of the haplotypes by their mean TG did not correspond to
their ranking by proportion of CHD events [58]. The three
highest risk-associated haplotypes carried APOA4 S347
and flanking markers. However, the next highest risk
haplotype was defined by APOA5 W19. The proportion
of events in carriers of this haplotype was 10% compared
to 6% for the sample mean [58]. The data from this study
suggest this risk may be due to the preponderance of
sdLDL in subjects carrying this haplotype.
Thus, the increased frequency of the  1131C/ 3G
haplotype in Japanese and Japanese Americans suggests
that genetic variation in APOA5, and possibly specifically
the  3A>G variant, is a major genetic determinant of both
LDL particle size and plasma TG levels among ethnic
Japanese. These data also confirm the multifactorial and
complex genetic interrelationships that determine both CHD
risk factors and CHD itself.Acknowledgements
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The APOA5 1259T>C polymorphism was identified with
an RFLP PCR-based assay using the endonuclease NdeI
(Invitrogen, Carlsbad, CA). Primers were designed to amplify
501 bp of the APOA5 gene, in the 3V-UTR surrounding the
SNP1 polymorphism, accession number ss3199913 [1]. A
base pair mismatch (C instead of a G) was placed three base
pairs from the 3V-end of the reverse primer resulting in the
creation of a NdeI restriction site making RFLP detection of
SNP1 possible. The IVS3 + 476G>A and the  1131T>C
polymorphisms were identified using fluorogenic TaqMank
probes and 5V nuclease-based genotyping (allelic discrimi-
nation) assays derived from previously described sequences
[1] (accession numbers ss3199914 and ss3199915, respec-
tively). The APOA5  3A>G variant, the S19W variant, and
a new insertion/deletion polymorphism in exon 1 were
identified with assays that utilized a PCR/dye terminator
cycle sequencing-based assay and are described in dbSNP
through NCBI under accession numbers ss4383596 and
ss4383597, respectively. Ten percent of identified alleles
were randomly reanalyzed to ensure accuracy.APOA5 SNP
and location
Forward primer (FP)
Reverse primer (RP)
Allele 1 probe (WT)
Allele 2 probe (MUT)
SNP1 (T/C) FP: 5V-CgAggAggTgCgCCAgCgACTTCAggCT
3V-UTR CTgCAgATAgCTgCCTTCACTCgCgC-3V
RP: 5V-gAgCACTgggAggCTgggTTTgCAAAgC
CCAgATTggggAgTCgCAggAggCTgCAT-3V
SNP2 (G/A) intron 3 FP: 5V-gATCAgTgCgCgATgACTTg-3V
(anti-sense probes) RP: 5V-gTCCTggAgAAggggACAgATAT-3V
WT: 5V-6FAMk-TgCTAgCCCCCATC-MGBN
MUT: 5V-VICR-TgCTAgCCTCCATCA-MGBN
SNP3 (T/C) promoter FP: 5V-CCCTgCgAgTggAgTTCAg-3V
RP: 5V-ggTTAAAgACCAACCACATCCC-3V
WT: 5V-VICR- TggggCAAATCTTACTTTCgC
MUT: 5V-6FAMk-TggggCAAATCTCACTTTC
Kozak (A/G), 5V-UTR; FP: 5V-CATgTCCCTTCgTCTCCTTCTT-3V
new I/D, exon 1;
and S19W (C/G), exon 2
RP: 5V-AgCTgTCTCCTCCCTTCgC-3VAppendix B
The APOA5 gene was amplified from each individual in
five overlapping segments, using gene-specific primers
containing either a universal forward (21M13,
TGTAAAACGACGGCCAGT) or reverse (M13reverse,
CAGGAAACAGCTATGACC) sequence. The following
specific primer pairs were used to amplify the APOA5
gene (listed as the forward and reverse primers, primer
annealing temperature):CCTTGCAGCCAAGTCTAATTCTA and AGTAGA-
GAAGTGCTTCCCAGGAG, 60 jC
GAACCTGTAGTGAAGCTTTCAGG and TTTGTCC-
CCGCTGGTCTG, 60 jC
TAACCAGGCCTCCCTCCAC and CTTCACCTCCTC-
CAACTCCTC, 64 jC
CTGACGGCCTGGATATCTGT and GCCAAGG-
CTCCCCAGACA, 56 jC
AGTTTCAACAAACAGACAGTGGC and CTTTCA-
GACATGGTCCAAATGAG, 60 jCOligomer
concentrations
(nM)
PCR conditions
(jC time)
TTCCgCCAggACACCTAC 200 95j 10 m
95j 30 s
CTggTgAATgTAATgCAT 200 75j 1 m
72j 1.5 m,
Cycles: 35,
75j 5 m
320 95j 2 m
320 95j 25 s
FQ-3V 40 64j 40 s
FQ-3V 48 Cycles: 42
280 95j 2 m
280 95j 25 s
TCC-TAMRAk-3V 48 65j 40 s
gCTC-TAMRAk-3V 36 Cycles: 40
200 95j 10 m
200 95j 30 s,
75j 1 m,
72j 1.5 m,
Cycles: 35,
75j 5 mAll amplification reactions were performed in 96-well
microtiter plate thermal cyclers (PTC 100, MJ Research,
Watertown, MA), using reaction volumes and conditions
described previously [59]. Following DNA amplification,
diploid PCR products were purified and sequenced with
dye-labeled forward or reverse universal primers, as de-scribed previously [59,60]. DNA polymorphisms were
identified using the PolyPhred program (version 4.0) [61]
after sequence chromatograms were base-called with the
Phred program and assembled with Phrap [62,63]. The base-
calling and genotyping accuracy of these programs has been
described previously [59].
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